A cannabinoid is one of a collection of complex chemical compounds that operates on cannabinoid receptors in cells that fluxuates neurotransmitter release in the brain. Cannabinoids for these receptors include the endocannabinoids, that are made naturally in the body by animals, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non psychotic effect. This paper will look at how cannabinoids can help the immune system with disease severity in the face of prostate cancer.
Here is the full scientific article if you wish to download it.
Prostate cancer may be alleviated by cannabinoids
In the light of findings suggesting that cannabinoids can impact the proliferation of numerous cancer cell types and that cannabinoid receptor expression is greater in prostate cancer cell lines than in non cancerous cells, this study highlighted whether the level of cannabinoid 1 receptor immunoreactivity in prostate cancer cell tissues is related to disease seriousness and outcome. Non cancerous and tumour tissue samples were taken from patients who were diagnosed with prostate cancer. Immunoreactivity which was scored in a total of 399 cases, was related to the epithelial cell membranes, with little staining in the stroma. A tumour immunoreactivity was related to a massively lower disease selective survival. A method called the cox proportional hazards regression suggested that the tumour immunoreactivity score and another called the Gleason score were independent prognostic variables. It is resulted that a high tumour immunoreactivity score is related to prostate cancer severity and outcome.
Future studies are needed to clarify cannabinoids potential in prostate cancer
Overall, the current study has developed the studies using cultured cells to show that a high immunoreactivity is related with a more serious type of the disease at diagnosis and a poorer outcome. Future studies magnifying other constituents of the endocannabinoid system in this studies patient series are clearly allowed, as are investigations of the cannabinoids receptor 1’s immunoreactivity in metastatic tissue. The discovery that the cannabinoid 1 receptor is related to disease outcome in the patients with Gleason scores of 6–7 and 6 alone is of possible clinical importance, given that treatment decisions are hard for such subjects.